Stock in Acorda Therapeutics Inc. jumped by more than 12 percent in early trading Monday on its announcement that a proof-of-concept trial showed Ampyra (dalfampridine) improved walking in people with post-stroke deficits such as impaired walking, motor and sensory function, and manual dexterity.